You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

osimertinib

Showing 26 - 50 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Trial in Tianjin (Osimertinib, Bevacizumab Biosimilar IBI305, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • Osimertinib
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Nsclc Trial in Spain (Repotrectinib, Osimertinib)

Recruiting
  • Nsclc
  • Málaga, Andalucia, Spain
  • +3 more
Jun 29, 2022

NSCLC Trial in Guangdong (SI-B001, Osimertinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Guangdong, Guangzhou, China
    Sun Yat-sen University Cancer Center (SYSUCC)
Jul 31, 2022

NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +3 more
Aug 1, 2022

Non Small Cell Lung Cancer Metastatic Trial in Worldwide (Osimertinib, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Dublin, Ireland
  • +24 more
Aug 23, 2022

NSCLC (NSCLC) Trial in Duarte, Dallas (Osimertinib, SABR)

Active, not recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Osimertinib
  • SABR
  • Duarte, California
  • +1 more
May 13, 2022

Metastatic Non Small Cell Lung Cancer Trial in Australia, Singapore (Osimertinib, Stereotactic Radiosurgery (SRS))

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Osimertinib
  • Stereotactic Radiosurgery (SRS)
  • Newcastle, New South Wales, Australia
  • +12 more
Nov 16, 2022

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Columbus

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jul 14, 2022

Non Small Cell Lung Cancer Trial in Durham, Columbus, Pittsburgh (osimertinib)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • osimertinib
  • Durham, North Carolina
  • +2 more
Jun 30, 2022

Lung Cancer Trial in China (osimertinib)

Recruiting
  • Lung Cancer
  • osimertinib
  • Changsha, China
  • +11 more
Aug 12, 2022

NSCLC Trial in Chattanooga, Nashville (Aumolertinib, Osimertinib)

Not yet recruiting
  • NSCLC
  • Chattanooga, Tennessee
  • +1 more
Aug 16, 2022

NSCLC Trial in Guangzhou (SKB264, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University, Cancer Center
Apr 14, 2023

Lung Cancer Trial in United States (Osimertinib, Platinum, Etoposide)

Recruiting
  • Lung Cancer
  • Osimertinib
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Jul 1, 2022

Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Orange,

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +8 more
  • Orange, California
  • +2 more
Aug 10, 2022

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in United

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +2 more
  • Osimertinib
  • Telaglenastat Hydrochloride
  • Birmingham, Alabama
  • +10 more
Jan 25, 2023

Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Biopsy
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 2, 2022

NSCLC Stage IIIB, NSCLC Stage IV Trial in Frankfurt (Osimertinib, Pemetrexed, Cisplatin)

Recruiting
  • NSCLC Stage IIIB
  • NSCLC Stage IV
  • Osimertinib
  • +3 more
  • Berlin, Germany
  • +8 more
Oct 25, 2022

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 Trial in United States

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +5 more
  • Osimertinib
  • +2 more
  • San Francisco, California
  • +3 more
Aug 17, 2022

Lung Cancer Trial in Worldwide (osimertinib)

Active, not recruiting
  • Lung Cancer
  • osimertinib
  • Aarhus, Denmark
  • +9 more
Apr 6, 2022

NSCLC, EGFR Activating Mutation, Brain Metastases Trial in Beijing (TY-9591, Osimertinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospitial,Chinese Academy of Medic
Jul 9, 2023

NSCLC, Lung Cancer, NSCLC Trial in United States (G1T38, Osimertinib)

Completed
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • Beverly Hills, California
  • +7 more
Sep 20, 2022

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung

Recruiting
  • Advanced Lung Non-Squamous Non-Small Cell Carcinoma
  • +8 more
  • Aurora A Kinase Inhibitor LY3295668
  • Osimertinib
  • Houston, Texas
    M D Anderson Cancer Center
Jun 29, 2022

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +4 more
  • Flt3/MerTK Inhibitor MRX-2843
  • Osimertinib
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Mar 8, 2022

NSCLC, EGFR-mutant Lung Cancers Trial in United States (osimertinib, Bevacizumab)

Completed
  • Non-small Cell Lung Cancer
  • EGFR-mutant Lung Cancers
  • Basking Ridge, New Jersey
  • +6 more
Mar 2, 2022